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Introduction
Transplantation today is a far cry from the ﬁ eld that 
encouraged many current practicing clinicians to take 
this career path. Th e results are much more predictable 
than they were 20 to 30  years ago and the investigative 
and therapeutic tools we have at our disposal are much 
more powerful. Some of the diseases we used to treat are 
rare or have vanished, such as analgesic nephropathy, to 
be replaced by a depressing avalanche of diabetic and 
hypertensive nephropathy in increasingly older patients. 
Th e pace of innovation over the last 20  years has been 
rapid and we have become used to seeing continuous and 
substantial improvements, but there is the concern that 
the ﬁ eld is stagnating, partly because those innovations 
have brought results that seem hard to improve upon. 
Th e excitement of innovation may have passed to another 
ﬁ eld – perhaps oncology, perhaps intraluminal inter ven-
tion – and we are left with the feeling in transplantation 
that we can only tidy up our results at the margins. In this 
paper I will review whether or not this situation is true 
and consider some of the challenges that are either with 
us or ahead of us.
The incidence and prevalence of treated and 
untreated end-stage kidney disease
Incidence of chronic kidney disease
How many people develop end-stage kidney disease 
(ESKD) remains a perennial question for clinicians, 
managers and health policy analysts as well as the 
treasuries that fund treatment. Th e answer is hard to ﬁ nd 
since the untreated patients die and are not to be found 
in the hospital statistics or in registries of dialysis or 
transplantation patients. Th e patients who die untreated 
may not be seen by specialist physicians or may never be 
admitted to a hospital; they may in fact never be diag-
nosed or ever be seen by a doctor in many countries. In 
advanced western economies, however, death certiﬁ cate 
records are one way of assessing the causes of death of 
the population, and while they have their weaknesses, 
these records can provide reasonable estimates of need.
Th e Australian Institute of Health and Welfare has 
compiled death records of patients identiﬁ ed as having 
died primarily of chronic kidney disease (CKD) and 
correlated them with the records of the Australian and 
New Zealand Dialysis and Transplant Registry to deter-
mine which patients had been treated and which had not 
been treated by dialysis or transplantation [1]. Th e 
resultant analysis demonstrated that most Australians 
under the age of 60 years had been treated by dialysis or 
transplantation, while most over 80  years old had not 
(Figure 1). Th at this is country speciﬁ c is clariﬁ ed by the 
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fact that the maximal combined incidence of both treated 
and untreated ESKD in Australia is lower than the United 
States incidence of treated ESKD. Th is fact and the great 
variation of incidence by population  – for example, the 
Aboriginal population in Australia has extremely high 
rates – highlights the need for a focus on prevention of 
CKD through active public health and therapeutic 
interventions. Th e past 5 years have, in Australia, seen a 
stabilizing of incidence of new dialysis patients younger 
than 75 years and now for 3 years a progressive decrease 
in new patients. No consideration of renal transplantation 
can thus ignore the relative investment needed in 
prevention of CKD, especially in the emerging and 
developing economies of the world, and the Australian 
experience suggests that this is a legitimate and realistic 
target.
Th e ﬁ rst Key Challenge is thus to prevent CKD and 
retard progression to ESKD.
Incidence of transplantation
Th e incidence of ESKD that is treated by renal trans-
plantation varies around the world, as can be seen in 
Figure 2 that is derived from the World Health Organi-
sation Global Observatory on Donation and Transplanta-
tion [2]. Th e highest rates of transplantation are thus seen 
in Croatia, Norway and Portugal through a combination 
of donation by both deceased and living donors, while 
Spain has the highest rate of deceased organ donation of 
any of the more populous nations. From these data one 
can derive a benchmark rate of over 50 kidney transplants 
per million population per annum. Th e vast majority of 
even the most developed countries with the highest 
Human Development Index scores are thus failing to 
reach this benchmark rate, which has been demonstrated 
to be possible. Th ere were approximately 75,000 kidney 
transplants globally in 2010, but this benchmark rate 
would call for 350,000 transplants, or four to ﬁ ve times 
the rate achieved today.
Th e second Key Challenge is thus to raise the rate of 
kidney transplantation to 50  or more transplants per 
annum per million population in all countries.
Costs of treatment
While there are many diﬃ  culties in estimating the cost of 
treating kidney disease, this has been estimated by many 
policy analysts, by industry and by lobby groups in many 
countries. None of the estimates or projections is aﬀ ord-
able. Dialysis and transplantation are expensive therapies 
and the cumulative impact of survival leads to escalating 
total costs that are straining the US Medicare budget and 
in most countries see a disproportionately high per cen-
tage of healthcare resources disbursed to a small sector of 
the population. Projections in Australia are that the total 
cost of treatment for ESKD will be between 
AUS $11.3 billion and AUS $12.3 billion by 2020, having 
risen from AUS $1 billion in 2009 [3].
Th e third Key Challenge is thus to reduce the total 
costs of treatment for ESKD by optimizing the rate of 
Figure 1. Comparison of treated and untreated end-stage kidney disease in Australia between 2003 and 2007. KRT, kidney replacement 
therapy. Reproduced with permission from [1].
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kidney transplantation and reducing the cost of dialysis 
and the cost per transplant.
Outcomes of transplantation
Patient survival
Th e most important outcome of transplantation from the 
patient’s perspective is their survival even in the event of 
failure of the graft. Th is has become a more certain 
outcome in the past decade but is still far from 
acceptable. Th e mortality rate for transplant recipients in 
the 1970s was as high as 40% in the ﬁ rst year and so we 
now congratulate ourselves on a mortality rate that in 
developed countries is approximately 3% at 1  year [4]. 
Comparison with the general population and the dialysis 
population demonstrates the superiority of transplant 
over dialysis, but also demonstrates a wide discrepancy 
between the transplant population and the general 
community [4]. In fact, the survival of transplant 
recipients by age cohort is more akin to the survival of 
the general population with a diagnosis of cancer [5]. 
Depending upon the age of the patient, the excess risk of 
death is up to 10-fold the normal population; or to put it 
another way, the risk of death for a transplant recipient is 
equivalent to that of an average person 30  years older. 
Perhaps there is not so much to congratulate ourselves on 
as there is to challenge ourselves with?
Causes of death
Th e causes of death after transplantation have been 
changing slowly over the past decades and also vary with 
the time after transplantation. Infection, cardiovascular 
disease and malignancy are the three most important 
causes of death. Th e death rates from cardiovascular 
disease in the Australian transplant population has 
decreased over the past 20  years from 1.8  deaths per 
100  patient-years in the mid-1980s to 0.9  deaths per 
100  patient-years in the mid-2000s, while infection has 
decreased from 0.7 to 0.3  deaths per 100  patient-years. 
Malignancy shows the reverse, with a slight increase 
from 0.6 to 0.8  deaths per 100  patient-years, and has 
almost become the commonest cause of death, sur-
passing combined cardiovascular diseases. If we are to 
impact beneﬁ cially on patient mortality there is more to 
be done with respect to all three main causes, but of the 
three we have the least armamentarium against cancer.
Th e fourth Key Challenge is to reduce the mortality 
rate after kidney transplantation through improving 
cardio vascular health, reducing infection risks, and 
detecting and treating cancer.
Graft survival
Th e live patient’s priority is clearly to have a functioning 
kidney transplant through avoiding rejection. Th is has 
been accomplished to a great degree in the ﬁ rst year after 
transplantation, with graft loss now quite rare from 
rejection. By weighting both sides of the scales we have 
achieved a remarkable reduction in acute rejection rates 
and also in graft loss from acute rejection. We have 
increased immunosuppressive potency but at the same 
time we have  – at least in the aﬄ  uent world  – also 
Figure 2. Total number of kidney transplants per million population. Total number of kidney transplants per million population correlated 
against the Human Development Index (HDI) for member states of the World Health Organisation (WHO). AFR, WHO African Region; AMR, WHO 
Region of the Americas; EMR, WHO Eastern Mediterranean Region; EUR, WHO European Region; SEAR, WHO South-East Asia Region; WPR, WHO 
Western Pacifi c Region. Reproduced with permission from [2].
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increased the use of prophylactic agents for the infectious 
agents against which we have eﬀ ective strategies  – 
cytomegalovirus and Pneumocystis jurovecii (Figure  3). 
Th is strategy has left our grafts at the mercy of infectious 
agents that we cannot today control, such as BK virus, 
and funguses that regularly take a toll in both the 
developed and emerging economies of the world.
Th e well-known Australian and New Zealand Dialysis 
and Transplant Registry analysis of long-term outcomes 
[5] demonstrates quite nicely the impact we have had on 
graft loss in the ﬁ rst year (Figure  4, top-left panel), 
contrasted with the relative failure to impact graft 
survival beyond 10 years (Figure 4, bottom-right panel). 
We have made a large impact on short-term outcomes 
and this is our success, but we have hidden our failure to 
impact the long term because it is hard to follow enough 
patients for long enough to even understand the crude 
outcomes, let alone visualize and investigate the causes of 
diﬀ erences in long-term results.
Causes of graft loss
Death with a functioning graft accounts for about one-
half of the graft losses in most series, with the remainder 
being attributable either to a miscellany of issues such as 
recurrence of glomerulonephritis, vascular thrombosis, 
technical complications and a few acute rejection losses, 
or to the constellation of causes of chronic progressive 
dysfunction of the graft. Variably named over the years as 
chronic rejection, chronic allograft nephropathy and now 
chronic allograft dysfunction, this condition is seen as a 
mystery by some and explicable by others [6].
Th e kidney has limited responses to injury and thus 
anything that exerts a negative impact on the kidney 
tends to lead to ﬁ brosis and atrophy of the tubules with 
glomerulosclerosis. A common misconception is that a 
particular kidney can only be aﬀ ected by one problem at 
a time. Th e injuries that contribute to chronic dys-
function start in the donor, and relate to the actual 
transplant procedure through the degree of ischemia; to 
Figure 3. Development of therapeutic agents in transplantation.
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the bouts of acute clinical and subclinical rejection that 
can occur in the early weeks (especially if untreated); as 
well as the nephrotoxicity of the calcineurin inhibitors we 
use to protect the kidney from rejection; and also the 
insidious damage resulting from chronic antibody-
mediated rejection. Th ere are no biological laws that 
restrict damage to only one of those entities.
Th e ﬁ fth Key Challenge is to reduce the rate of graft 
loss through focus on subclinical phenomena, under-
stand ing the role of antibodies to donor HLA antigens 
and improving the way in which we use nephrotoxic 
drugs to retain their short-term advantages but 
ameliorate their long-term disadvantages.
Innovation in transplantation
Th e optimist will look at what we have achieved in the 
clinic over the past 40 years and identify the truth of the 
impact of sometimes serendipitous innovation. Th ese 
same people will look forward to innovation to provide 
the next wave of improvements in our outcomes. Th ere 
are many that say the days of relying on serendipity are 
behind us, so perhaps it will be through the science of 
today that we will see the clinical advances of tomorrow. If 
so, then I would nominate biomarkers and clinical toler-
ance strategies as the most likely contenders for the crown.
Biomarkers
Th e ﬁ rst and most successful biomarker in renal trans-
plantation was serum creatinine, and it would be fair to 
suggest that we owe the success of renal transplantation 
to measuring this molecule reliably and at low cost to 
predict when increased immunosuppression is needed to 
combat acute rejection. Th ere is a substantial stream of 
research directed at identifying new molecules that can, 
in urine or blood, predict both short-term and long-term 
outcomes such as acute allograft rejection and graft 
ﬁ brosis [7]. Th ere is also a clear line of research that is 
aimed at using biomarkers to identify the cellular 
mechanisms involved in development of spontaneous 
tolerance.
Th e promise of biomarkers in other ﬁ elds, such as 
cancer therapy, is that the combination of a biomarker 
Figure 4. Graft survival in Australia and New Zealand from the 1960s to today. Short-term, medium-term and long-term graft survival in 
Australia and New Zealand from the 1960s to today. Reproduced with permission from [4].
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and a speciﬁ c therapeutic agent will advance the results 
for particular patients. Can this strategy lead to the best 
use of immunosuppression where the increased visibility 
of humoral rejection mechanisms has directed our 
attention to anti-B cell-strategies, yet the precise B-cell 
proﬁ le seems to be relevant to identifying spontaneously 
tolerant individuals? Can biomarkers solve our conun-
drums around HLA-sensitized recipients? Th e funda-
mental uncertainty over what is and what is not patent-
able may be behind us with recent pivotal decisions in the 
United States – fundamental laws of nature biology and 
genetics are not patentable, but the tests that measure 
them and that are applicable in a nonobvious manner to 
modify therapy are patentable.
Th e sixth Key Challenge is to use biomarkers to better 
guide and individualize therapy.
Tolerance
Medawar and his colleagues in the 1950s conceived and 
demonstrated that allogeneic organ transplantation did 
not need immunosuppression through strategies designed 
to either evade the alloimmune response or suppress, 
delete or regulate it. Th ree clinical programs in Boston, 
Stanford and Chicago have shown that this may be 
possible in man, in which a total of about 40  patients 
have so far been reported [8-10].
Th e strategy for creating mixed allogeneic chimerism 
has been achieved in slightly diﬀ erent ways in the three 
programs. In Boston, simultaneous full bone marrow and 
renal transplantation from the same donor was successful 
in six patients with myeloma and HLA-identical siblings. 
Th is was followed with haplo-identical donors augmen-
ted by T cell depletion by antibodies and thymic irra-
diation. Th e Stanford group has undertaken 16 HLA-
matched donor transplants with total lymphoid irradia-
tion, anti-thymocyte globulin, and donor CD34+ hemato-
poietic progenitor cells and T cells. Louisville and 
Chicago have reported eight patients treated with total 
body irradiation, nonmyeloablative chemotherapy and an 
HLA-mismatched renal transplant from a living donor, 
followed on day +1 with infusion of tolerance-promoting 
facilitator cells and mobilized hematopoietic stem cells. 
Five of these eight patients have been weaned oﬀ 
immunosuppression.
Th ese clinical outcomes are of course exciting but there 
is much work to be undertaken before this approach can 
be seen as an acceptable alternative to conventional 
trans plantation. Perhaps the bar has been set too high 
and what we should seek instead is deﬁ nition of those 
patients for whom a stable state may be achieved with 
low levels of immuno suppression. We must be mindful of 
the patients unlikely to be managed through tolerance 
induction strategies, including those sensitized with HLA 
antibodies and perhaps those with a risk of recurrent 
glomerulonephritis, and we are as yet uncertain of the 
long-term outcomes.
Th e seventh Key Challenge is formally to examine an 
optimized tolerance protocol in an extensive clinical trial.
Conclusions
Despite excellent results from renal transplantation there 
are several key challenges today, reordered to suggest the 
relative importance and chance of reaching these goals:
• To raise the rate of kidney transplantation to 50 or 
more transplants per annum per million population in 
all countries.
• To reduce the mortality rate after kidney 
transplantation through improving cardiovascular 
health, reducing infection risks and detecting and 
treating cancer.
• To reduce the rate of graft loss through focus on 
subclinical phenomena, understanding the role of 
antibodies to donor HLA antigens and improving the 
way in which we use nephrotoxic drugs to retain their 
short-term advantages but ameliorate their long-term 
disadvantages.
• To prevent CKD and retard progression to ESKD.
• To reduce the total costs of treatment for ESKD.
• To use biomarkers to better guide and individualize 
therapy.
• To examine an optimized tolerance protocol in an 
extensive clinical trial.
Th ere is indeed work still ahead for a generation of 
research scientists and clinicians.
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